Skip to main content
Remdesivir stockpiling could help push COVID drug into profitable territory for Gilead: analyst - FiercePharma 06-Jun-2020
Remdesivir stockpiling could help push COVID drug into profitable territory for Gilead: analyst - FiercePharma
Assuming Gilead will price its COVID-19 drug remdesivir at $5,000 per course in the U.S., and governments around the world start building stockpiles next year, the company could bring in $7.6 billion in sales of the drug in 2022, with a decent profit margin, …
More...